Cargando…

Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells

Sorafenib is a multikinase inhibitor and is effective in treating hepatocellular carcinoma (HCC). However, it remains unknown whether sorafenib induces the alteration of protein glycosylation. The present study treated HCC MHCC97L and MHCC97H cells with a 50% inhibitory concentration of sorafenib. F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Tianhua, Liu, Riqiang, Zhang, Shu, Guo, Kun, Zhang, Qinle, Li, Wei, Liu, Yinkun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494657/ https://www.ncbi.nlm.nih.gov/pubmed/28693200 http://dx.doi.org/10.3892/ol.2017.6177

Ejemplares similares

GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness
por: Jiang, Kai, et al.
Publicado: (2016)

Histidine-rich glycoprotein function in hepatocellular carcinoma depends on its N-glycosylation status, and it regulates cell proliferation by inhibiting Erk1/2 phosphorylation
por: Zhang, Qinle, et al.
Publicado: (2015)

The Transcriptional Profiling of Glycogenes Associated with Hepatocellular Carcinoma Metastasis
por: Liu, Tianhua, et al.
Publicado: (2014)

Discovering potential serological biomarker for chronic Hepatitis B Virus-related hepatocellular carcinoma in Chinese population by MAL-associated serum glycoproteomics analysis
por: Liu, Tianhua, et al.
Publicado: (2017)

Oct4 induces EMT through LEF1/β-catenin dependent WNT signaling pathway in hepatocellular carcinoma
por: Sun, Lu, et al.
Publicado: (2017)

Clusterin Protects Hepatocellular Carcinoma Cells from Endoplasmic Reticulum Stress Induced Apoptosis through GRP78
por: Wang, Cun, et al.
Publicado: (2013)

Assessment of Hepatocellular Carcinoma Metastasis Glycobiomarkers Using Advanced Quantitative N-glycoproteome Analysis
por: Liu, Tianhua, et al.
Publicado: (2017)

Protein glycosylation alterations in hepatocellular carcinoma: function and clinical implications
por: Wang, Yifei, et al.
Publicado: (2023)

Sorafenib Metabolism Is Significantly Altered in the Liver Tumor Tissue of Hepatocellular Carcinoma Patient
por: Ye, Ling, et al.
Publicado: (2014)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

Aided Diagnosis of Hepatocellular Carcinoma Using Serum Fucosylated Haptoglobin Ratios
por: Shang, Shuxin, et al.
Publicado: (2017)

Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy
por: Li, Jun, et al.
Publicado: (2018)

Characterization of glycosylation regulator-mediated glycosylation modification patterns and tumor microenvironment infiltration in hepatocellular carcinoma
por: Zhao, Linlin, et al.
Publicado: (2022)

miR-222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma
por: Liu, Kai, et al.
Publicado: (2021)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
por: Chen, Xin, et al.
Publicado: (2022)

Exploration of Sorafenib Influences on Gene Expression of Hepatocellular Carcinoma
por: Wang, Huancheng, et al.
Publicado: (2020)

The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma
por: Shi, Yi, et al.
Publicado: (2021)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

The Roles of GSK-3β in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma
por: Zhang, Shuaishuai, et al.
Publicado: (2020)

Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma
por: Zhang, Xinning, et al.
Publicado: (2022)

3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy
por: Zhao, Fangfang, et al.
Publicado: (2021)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1
por: Garten, Antje, et al.
Publicado: (2019)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
por: Li, Xuguang, et al.
Publicado: (2020)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

CISD2 Promotes Resistance to Sorafenib-Induced Ferroptosis by Regulating Autophagy in Hepatocellular Carcinoma
por: Li, Bowen, et al.
Publicado: (2021)

Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib
por: Liu, Daizhong, et al.
Publicado: (2015)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
por: Liu, Kai-Cai, et al.
Publicado: (2020)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes
por: Xie, Yong, et al.
Publicado: (2021)

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
por: Kong, Fan-Hua, et al.
Publicado: (2021)

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
por: Tian, Xinchen, et al.
Publicado: (2022)

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Ma, Yongfang, et al.
Publicado: (2021)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cd7hd6sm5t77u25oma9f0ughlk